Abstracts can only be submitted via the online abstract submission system. Abstracts sent by post or email will not be accepted. No exceptions will be made.
The internet abstract submission system works best with Internet Explorer 10.0 or higher and Mozilla Firefox 5.0 or higher and Chrome 16 and Apple Safari 3 or higher.
- Abstract submission must be in one of the three different categories:
a. Medical or Research Professional / Clinician
b. Health Professional in Rheumatology / Practice and Research
c. PARE Member / Patient
The categories are subdivided into topics (Abstract topics).
The correct category and topic must be selected to ensure correct scoring.
The content of the abstract must be topic related.
- Splitting of data originating from the same study across several abstracts and/or topics is not permitted and will lead to rejection of the abstracts.
- It is mandatory to use the Word template provided by the system. Please read all instructions carefully before preparing your abstract.
- For standardisation, the acceptable length of the abstract is not more than 3600 characters and 55 lines, authors’ details and headers included. This also includes non-visible characters such as spaces as well as punctuation.
- The abstract is structured into the following sections:
a. A title which clearly indicates the nature of the investigation
Abstracts can be saved in “Draft” status to be re-edited and modified until the submission deadline (31 January 2019, 23:59 CET).
- Therefore, the submitter will be required to create an EULAR Congress user account.
- Abstracts fulfilling all criteria can be saved in “Final submission” status. Only abstracts in “Final submission” status will be regarded as successfully submitted and considered for the congress. Abstracts in “Final submission” status can be re-edited and modified until the submission deadline (31 January 2019, 23:59 CET).
- An abstract can only be submitted if the “Rules and Regulations, including the EULAR embargo rules” on the online abstract form are read and accepted.
- Conflict of interest: It is the intent of EULAR to provide high quality sessions focused on educational content that is free from commercial influence or bias. Thus the submitting author of an abstract is requested to declare any potential conflicts of interest for all authors during the abstracts submission.
For clinical abstract submissions, the presenting author can be any of the listed authors without affiliations to industry.For basic and translational abstract submissions, the presenting author can be any of the listed authors.
- The inclusion of trade names/brand names is not allowed in the abstract. The mentioning of agents/molecules must follow the scientific standard for publications.
- Abstracts accepted for the congress are subject to the “EULAR embargo rules” as published in the right column on this page or at end of this page for mobile view. With the submission of an abstract the authors agree to the embargo rules.
- The corresponding author has the right to grant, and does grant, on behalf of all authors an exclusive licence on a worldwide basis to the BMJ Publishing Group Ltd and EULAR to publish the abstract (if accepted) in any media and to exploit all subsidiary rights.
Only abstracts that contain original data can be submitted.
Abstracts should not be submitted if the following applies:
a. the abstract contains data that has been published or accepted for publication in a print or online journal
b. the abstract contains data that was presented at a scientific meeting more than 12 months prior to EULAR 2019
Abstracts containing data that has been presented or will be presented at a different scientific meeting between 01 June 2018 and 31 January 2019 can be submitted. Submission of an abstract that will be presented elsewhere between 1 February 2019 and 31 March 2019 is possible if acceptance is still pending at the time of the abstract submission (31 January 2019). These facts must be indicated on the submission form.
Abstracts submitted for publication or to a scientific meeting, but are pending acceptance, can be submitted without restrictions. However, once the abstract has been accepted by EULAR it is automatically subject to the EULAR embargo rules
The reviewers will judge the abstracts according to the scientific or clinical value, relevance to EULAR, suitability of methods to aims, conclusions confirmed by objective results, objectivity of statements, description of methods used, ethics, originality of work, standard of English and overall impression.
Please ensure that your abstract does not contain spelling, grammatical or scientific errors, as it will be reproduced exactly as submitted. No proofreading will be done.
- Abstract acceptance will be in one of three categories: oral presentation, poster presentation, publication only
- Should the abstract be selected for oral presentation, the authors, represented by the presenting author will be required to sign an agreement to grant EULAR the right to record the presentation
(audio and slide) and subsequently use it for educational purposes (with or without a fee).
The full text of the agreement, the publication licence, can be found on the right side of the column.
- Accepted abstracts will be published in a supplement to the Annals of Rheumatic Diseases (ARD). Information on accepted abstracts (title and authors) will also be available online about one month prior to the congress. Published abstracts will be available in the EULAR Abstract Archive during and after the congress.
- The submission of an abstract constitutes a formal commitment by the presenting author to present the abstract (if accepted) orally or as a poster in the session and the time assigned by the EULAR Scientific Programme Committee. We therefore recommend submitters of abstracts to register for the congress at the time of abstract submission.
- Abstracts not adhering to these guidelines will be rejected. If you do not agree with any of these rules, you should not submit an abstract. The final decision about acceptance of an abstract will be taken by the EULAR Scientific Programme Committee. EULAR does not communicate, nor enter into correspondence on the reasons for acceptance/rejection of an abstract.
- If the presenting author needs to be changed, a request, indicating the listed co-author who takes over the presentation, needs to be sent to MCI no later than 15 April 2019.
- If you need to withdraw your abstract, a written statement listing the reasons for this decision must be sent to the EULAR Secretariat or MCI not later than 1 April 2019.
Instructions for abstract presentations
- If an abstract is selected for oral presentation, the presenting author, as specified at submission, will be requested to present it in the assigned session. Details will be communicated to the author by mid-April 2019.
- If the abstract is selected for oral presentation, the authors, represented by the presenting author, will have to sign an agreement to grant EULAR the right to record the entire presentation (audio and slide) and subsequently use it for educational purposes (with or without a fee).
- If an abstract is accepted as a poster presentation, the presenting author will be requested to be available for discussion during the corresponding poster viewing session.
- Posters will be set up close to the exhibition area.
- For further information contact: email@example.com